These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 35114868)

  • 1. Novel systemic treatment approaches for metastatic pancreatic cancer.
    Dorman K; Heinemann V; Kobold S; von Bergwelt-Baildon M; Boeck S
    Expert Opin Investig Drugs; 2022 Mar; 31(3):249-262. PubMed ID: 35114868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
    Tarannum M; Vivero-Escoto JL
    Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
    Singh RR; O'Reilly EM
    Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of pancreatic cancer therapy resistance by chemokines.
    Gautam SK; Basu S; Aithal A; Dwivedi NV; Gulati M; Jain M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):69-80. PubMed ID: 36064086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
    Yu Y; Schuck K; Friess H; Kong B
    Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma.
    Alvarez MA; Freitas JP; Mazher Hussain S; Glazer ES
    J Gastrointest Cancer; 2019 Jun; 50(2):207-213. PubMed ID: 30891677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma.
    Gautam SK; Batra SK; Jain M
    Mol Cancer; 2023 Jul; 22(1):118. PubMed ID: 37488598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
    Tesfaye AA; Kamgar M; Azmi A; Philip PA
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):131-148. PubMed ID: 29254387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
    Babiker HM; Karass M; Recio-Boiles A; Chandana SR; McBride A; Mahadevan D
    Expert Opin Investig Drugs; 2019 Jul; 28(7):583-592. PubMed ID: 31215251
    [No Abstract]   [Full Text] [Related]  

  • 13. Uncovering key targets of success for immunotherapy in pancreatic cancer.
    Pretta A; Lai E; Persano M; Donisi C; Pinna G; Cimbro E; Parrino A; Spanu D; Mariani S; Liscia N; Dubois M; Migliari M; Impera V; Saba G; Pusceddu V; Puzzoni M; Ziranu P; Scartozzi M
    Expert Opin Ther Targets; 2021 Nov; 25(11):987-1005. PubMed ID: 34806517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
    Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S
    Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and Emerging Therapies in Metastatic Pancreatic Cancer.
    Manji GA; Olive KP; Saenger YM; Oberstein P
    Clin Cancer Res; 2017 Apr; 23(7):1670-1678. PubMed ID: 28373365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Therapeutics for Pancreatic Adenocarcinoma.
    Lowery MA; O'Reilly EM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far.
    Wong W; Alouani E; Wei A; Ryu YK; Chabot JA; Manji GA
    Semin Oncol; 2021 Feb; 48(1):57-68. PubMed ID: 33965249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
    Al Haddad AH; Adrian TE
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation therapies for pancreatic cancer.
    Buckley CW; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2024; 18(1-3):55-72. PubMed ID: 38415709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination immunotherapy for pancreatic cancer: challenges and future considerations.
    Gössling GCL; Zhen DB; Pillarisetty VG; Chiorean EG
    Expert Rev Clin Immunol; 2022 Nov; 18(11):1173-1186. PubMed ID: 36045547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.